| 8.48 -0.09 (-1.05%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.85 | 1-year : | 12.04 |
| Resists | First : | 9.29 | Second : | 10.31 |
| Pivot price | 8.39  |
|||
| Supports | First : | 7.63 | Second : | 6.35 |
| MAs | MA(5) : | 8.19 |
MA(20) : | 8.68 |
| MA(100) : | 9.43 |
MA(250) : | 8.41 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 41 |
D(3) : | 28.1 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 12.75 | Low : | 5.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CMPS ] has closed below upper band by 43.5%. Bollinger Bands are 50.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.86 - 8.9 | 8.9 - 8.93 |
| Low: | 8.22 - 8.27 | 8.27 - 8.3 |
| Close: | 8.41 - 8.48 | 8.48 - 8.54 |
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Wed, 01 May 2024
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model - Green Market Report
Tue, 30 Apr 2024
COMPASS Pathways (NASDAQ:CMPS) Trading 5.4% Higher - MarketBeat
Tue, 30 Apr 2024
(CMPS) Investment Analysis and Advice - Stock Traders Daily
Mon, 29 Apr 2024
COMPASS Pathways plc (CMPS) and Journey Clinical establish research collaboration agreement to inform the ... - StreetInsider.com
Thu, 25 Apr 2024
COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut? (CMPS) - Seeking Alpha
Wed, 24 Apr 2024
COMPASS Pathways plc (NASDAQ:CMPS) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 68 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 28.3 (%) |
| Held by Institutions | 39.1 (%) |
| Shares Short | 3,130 (K) |
| Shares Short P.Month | 3,740 (K) |
| EPS | -2.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.64 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -58.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.82 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -97 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -3.66 |
| PEG Ratio | -1.1 |
| Price to Book value | 2.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|